Clinical trial sites at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

19 clinical trial sites are at CTAD 2026 — 26 presentations on the program. Most represented: Tennessee Memory Disorders Foundation (3 on the program), Adams Clinical (2 on the program), Irvine Clinical Research (2 on the program). 6 of them have their own page in this guide. As of Oct 8, 2026.

All 315 organizations at CTAD 2026 →

Showing 1–17 of 19 organizations

Organization	CTAD 2026 Attendance
Tennessee Memory Disorders Foundation Knoxville, Tennessee
tmdf.org Clinical trial sites Knoxville nonprofit memory clinic that diagnoses and treats dementia, gives infusion therapies and runs regional Alzheimer's trials.	Poster Wed Nov 18 7:15am–5:30pm Evaluation of Alzheimer’s Blood Based Biomarkers in Race, Sex, Education, FAST and APOE β4 Carrier Status Evaluation of Alzheimer’s Blood based biomarkers in race, sex, education, FAST and APOE β4 Carrier Status (P278) Blood and CSF biomarkers Poster Thu Nov 19 7:15am–5:00pm Patient Outcomes and Real-World Treatment Review and Assessment of Infusion Therapies with Donanemab (P490) Anti-amyloid and anti-tau therapies · Real-world data and access Poster Thu Nov 19 7:15am–5:00pm Patient Outcomes and Real-World Treatment Review and Assessment of Infusion Therapies with Lecanemab (P491) Anti-amyloid and anti-tau therapies · Real-world data and access
Adams Clinical Watertown, Massachusetts
adamsclinical.com Clinical trial sites Independent clinical research site running psychiatry and neurology trials, including Alzheimer's disease studies.	Poster Thu Nov 19 7:15am–5:00pm Neighborhood Deprivation as a Moderator of the Association between Travel Time and Alzheimer’s Disease Clinical Trial Enrollment and Completion (P379) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Age-Dependent Sensitivity of the MMSE for Detecting Amyloid-Confirmed Alzheimer’s Disease (P389) Trial design and endpoints · Rising Stars Showcase
Irvine Clinical Research Irvine, California
irvineclinical.com Clinical trial sites Southern California clinical research site network running Alzheimer's and other central nervous system trials.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Episodic Memory Testing in TRAVELLER and TRONTIER: Evaluating the Relationship Between the International Shopping List Test (ISLT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (P031) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Optimizing Pre-Screening in Alzheimer’s Disease Clinical Trials: Using SLUMS Delayed Memory Index to Minimize Screen Failures and Maximize Inclusion (P512) Trial design and endpoints
K2 Medical Research Maitland, Florida
k2med.com Clinical trial sites Florida clinical research site network focused on Alzheimer's and memory-loss trials.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Population-Adjusted Alzheimer’s Clinical Trial Capacity in the United States: Reassessing the Perception of Site Saturation in High-Burden States (P145) Trial design and endpoints Poster Wed Nov 18 7:15am–5:30pm Blood-Based and Digital Biomarker Strategies Are Reshaping Alzheimer’s Clinical Trial Recruitment, Cohort Readiness, and Site Operations (P256) Trial design and endpoints · Blood and CSF biomarkers
NeuroClnx Glasgow, UK
neuroclnx.com Clinical trial sites UK clinical research site network with clinics in Glasgow and Warrington running Alzheimer's and other neurology trials.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue C2N Eligibility, APOE genotype Identification, Amyloid Confirmation. Results from the AHEAD 3-45 programme at Neuroclnx Glasgow. (P026) Blood and CSF biomarkers · Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Limitations of Cognitive Pre-sreening for Amyloid Enrichment in Early Alzheimer’s Disease Trials. Results from Evoke programme at Neuroclnx Glasgow (P421) Trial design and endpoints
TN The Neurology Center of Southern California Carlsbad, California
	Poster Thu Nov 19 7:15am–5:00pm Implementing the CMS GUIDE Dementia Care Model in a Community Neurology Practice with Digital Tools, Standardized Scales, Community Partners and Embedded Clinical Trial Recruitment (P460) Real-world data and access Poster Thu Nov 19 7:15am–5:00pm Implementation of a Standardized, Digitally Enabled Memory Clinic Pathway Accelerates Diagnosis and Improves Early Alzheimer’s Disease and Mild Cognitive Impairment Detection in Community Neurology (P508) Real-world data and access · Digital assessment and AI
AN Abington Neurological Associates Elkins Park, Pennsylvania
	Poster Thu Nov 19 7:15am–5:00pm Frequency and Predictors of Non-Progression in Lecanemab-Treated Alzheimer’s Disease: A Retrospective Cohort Study (P509) Anti-amyloid and anti-tau therapies · Real-world data and access
AN Alzheimer's Neurology and Infusion Centers of New England Foxborough, Massachusetts
	Poster Thu Nov 19 7:15am–5:00pm Lecanemab Treatment in a New England Alzheimer’s Disease Center: Real-World Outcomes From a Single-Center, Retrospective Case Series (P406) Anti-amyloid and anti-tau therapies · Real-world data and access
Basil Clinical New York, New York
basilclinical.com Clinical trial sites Clinical research site in Queens, New York, running industry-sponsored trials, including in Alzheimer's disease.	Poster Wed Nov 18 7:15am–5:30pm Racial and Ethnic Differences in Blood-Based Biomarkers of Alzheimer’s Disease Risk (P286) Blood and CSF biomarkers
CC California Clinical Trials Medical Group Glendale, California
	Poster Wed Nov 18 7:15am–5:30pm Comparing results from three Alzheimer’s Disease plasma biomarker tests in a prescreen study in healthy elderly participants (P308) Blood and CSF biomarkers · Trial design and endpoints
First Choice Neurology Medley, Florida
fcneurology.net Clinical trial sites Physician-owned South Florida neurology practice that runs clinical research centres for dementia and other neurology trials.	Poster Thu Nov 19 7:15am–5:00pm Real-World Patient-Reported Outcomes with Subcutaneous Lecanemab Treatment in Early Alzheimer’s Disease in the United States: A Case Series (P413) Anti-amyloid and anti-tau therapies · Real-world data and access
JR JEM Research Institute Atlantis, Florida
	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue ALTITUDE-AD: Baseline characteristics of participants randomized in a phase 2 trial of sabirnetug in early Alzheimer’s disease (P015) Anti-amyloid and anti-tau therapies
Minneapolis Clinic of Neurology Minneapolis, Minnesota
	Talk Wed Nov 18 11:00am–11:40am Part of Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings At-Home Subcutaneous Lecanemab Administration: A Multicenter, Real-World, Retrospective Study (LEADER) Anti-amyloid and anti-tau therapies · Real-world data and access
Re:Cognition Health London, UK
recognitionhealth.com Clinical trial sites UK private memory clinics that run clinical trials in Alzheimer's and other brain diseases and offer newer Alzheimer's treatments.	Poster Wed Nov 18 7:15am–5:30pm How Re:Cognition Health (RCH) has Fast Tracked Patients to Receive Amyloid Targeted Treatment (ATT) (P359) Real-world data and access · Anti-amyloid and anti-tau therapies
RM Rocky Mountain Research and Consulting Colorado Springs, Colorado
	Poster Thu Nov 19 7:15am–5:00pm Retrospective analysis of aducanumab and lecanemab treatment switches to donanemab in Alzheimer’s disease (AD) patients with mild cognitive impairment (MCI) or mild dementia stage of disease[TS1] and presence of amyloid beta pathology (P510) Anti-amyloid and anti-tau therapies · Real-world data and access
SC Shankle Clinic for Memory and Cognition Newport Beach, California
	Poster Wed Nov 18 7:15am–5:30pm Latent Cognitive Processes Exhibit Compensatory Behavior for Neurodegeneration (P327) Trial design and endpoints
Synapticure Chicago, Illinois
synapticure.com Clinical trial sites Telehealth neurology provider offering specialist care, including anti-amyloid treatment, for Alzheimer's, Parkinson's and ALS.	Poster Thu Nov 19 7:15am–5:00pm Fully Remote Telehealth Evaluation and Delivery of Amyloid-Targeted Therapy in Early Symptomatic Alzheimer’s Disease: Feasibility and Initial Experience (P440) Real-world data and access · Anti-amyloid and anti-tau therapies

Instantly find 20 buyers from clinical trial sites

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction

Instantly find 20 buyers from clinical trial sites

Browse CTAD 2026 by